Merck

WHCD Shooting, DOJ Ends Powell Probe, Musk Vs. Altman and More in Morning Squawk

Rick Winningham: Building Leaders Behind the Pipeline

Diagonal Banks Another $125M for ‘Clustering’ Antibody Drugs

Merck Backs Off Revolution After Failing To Agree on Price: WSJ

WHO Prioritizes Three Experimental Treatments for Bundibugyo Ebola Strain

Merck Completes $5.3 B Purchase of Terns, Adding Oral CML Drug TERN‑701

Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes

Clinical Trial Failures of 2026

FDA Approves KEYTRUDA® (Pembrolizumab) and KEYTRUDA QLEX™ (Pembrolizumab and Berahyaluronidase Alfa-Pmph), Each With WELIREG® (Belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma (ccRCC)

AbbVie, Amgen, Lilly Lead Calls for FDA To Update Post-Approval Change Rules

Pfizer and the Broader Push to Improve Cold Chain Visibility

Iridius Raises $8.6M Seed Round to Build Compliance-by-Design AI Platform for Regulated Enterprise Workflows

Hims & Hers Expands Personalized Digital Healthcare Platform

GLP‑1 Drugs Linked to 35% Lower Breast Cancer Risk, New ASCO Data Show

How Merck Plans to Set a Buffer for Keytruda's Patent Cliff

FDA Lifts Partial Hold on Merck, Daiichi's Phase 3 Lung Cancer Study

S&P 500, Nasdaq Nab Best Weeks Since November: Stock Market Today

Eli Lilly Raises $9 Billion in Record Investment‑Grade Bond Offering to Finance Acquisitions

Breast Cancer Treatments Heat Up: Six Therapies Poised to Transform Patient Outcomes

Evercore ISI Says Sun Pharma Deal Talk for Organon & Co. (OGN) Lacks Confirmation, Remains Speculative

Healthtech, Biotech: Why the UK Is Emerging as an Essential Hub

Servier Signs €1bn-Plus AI Pact with Iktos

FDA Grants Priority Review to Ifinatamab Deruxtecan for Treated Small Cell Lung Cancer

AI’s Next Frontier in Science Isn’t Thinking Faster. It’s Doing the Work.

FDA Sets Feb. 1 Launch Date for PreCheck Pilot To Strengthen Domestic Supply Chain

Regeneron Shares Tumble 6% After Phase 3 Melanoma Trial Misses Statistical Significance

4 Troubled Targets that Have Thwarted Biopharma

Moderna Gets $50 Million to Develop mRNA Ebola Vaccine Against Bundibugyo

Galactose Alters Early-Life Development and Exerts Sex-Specific Nutritional Programming Effects on Lifespan in Drosophila Melanogaster

Tuneable Peptide Biotech Parabilis Files IPO

Former Sen. Ben Sasse Shines the Spotlight on a Possible Breakthrough for Pancreatic Cancer

ASCO26: Key Readouts in Lung Cancer

Op-Ed: Commercial Demand in LEO Is Lacking. The Government Can Help.

Eli Lilly to Acquire Kelonia Therapeutics in $7 B Cash Deal

Merck Splits Operations to Separate Oncology From Non-Cancer Drugs

ASCO26: Solid Tumour Data Readouts Outline Merck & Co’s Oncology Prowess

Dow Jones Slides 322 Points as 30‑Year Treasury Yield Hits 19‑Year High

European Stocks Rally 0.8% on Mining, Energy and Tech Gains Amid Iran Conflict

This Pill May Help Pancreatic Cancer Patients Live Longer

BBOT Shakes up Leadership as RAS Competitors Get More Visibility

Alteogen Wins PTAB Ruling, Halting Halozyme's Challenge to ALT‑B4 Manufacturing Patent

The ERP Problem that AI Was Built to Solve

‘Almost Like a Religion’: Pfizer CEO Slams RFK Jr.’s 'Anti-Science' Vaccine Policies

Flagship CEO Calls Out Attacks on Science, Warns of China Dominance

PharmaShots Quarterly Outlook: The Forces Reshaping Biopharma in Q1 2026

LogicMonitor Defines the Autonomous IT Era with AI That Sees, Reasons, and Acts

Pfizer’s Oncology Sales Poised for Growth Ahead of Q1 Earnings

Permittivity Provides an In-Line Cell Health Early-Warning System

Overmedicalization? RFK Jr.’s Antidepressant Crackdown Raises Conflict Questions over His Fee Stake in Wisner Baum, the Tort Firm Built on Suing Drug Makers

The Ebola Virus

Merck to Acquire Cidara Therapeutics to Advance Universal Flu Vaccine

MSD Completes $5.3B Acquisition of Terns Pharmaceuticals

Merck Exercises Option to License Evaxion's EVX‑B3 Infectious Disease Vaccine Candidate

Solve Therapeutics Raises $120M in Oversubscribed Funding Round

Merck to Acquire Terns Pharmaceuticals for $6.7B